Jaka jest cena za Intellipharmaceutics International Inc. (IPCIF)

Cena za Intellipharmaceutics International Inc. (IPCIF) wynosi $0.15

Jaka jest kapitalizacja rynkowa dla Intellipharmaceutics International Inc. (IPCIF)

Kapitalizacja rynkowa dla Intellipharmaceutics International Inc. (IPCIF) wynosi $4.96M

Intellipharmaceutics International Inc. (IPCIF) Marża Operacyjna

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.

Rok	Marża operacyjna	Zmień
2026 (TTM)	-4,336.82%	0.00%
2022	-4,336.82%	0.00%
2021	-4,336.82%	1,356.53%
2020	-297.75%	-10.80%
2019	-333.80%	-57.10%
2018	-778.07%	418.13%
2017	-150.17%	-65.75%
2016	-438.41%	152.31%
2015	-173.76%	331.38%
2014	-40.28%	-90.98%
2013	-446.40%	-95.27%
2012	-9,447.17%	509.60%
2011	-1,549.72%	273.68%
2010	-414.72%	0.00%
2009	0.00%	0.00%
2008	0.00%	0.00%
2007	0.00%	0.00%
2006	0.00%	0.00%
2005	0.00%	0.00%
2004	0.00%	0.00%
2003	0.00%	0.00%
2002	0.00%	-100.00%
2001	-1,046,045.90%	42.56%
2000	-733,774.14%	13,744.82%
1999	-5,299.99%	0.00%

Rok

Marża operacyjna

Zmień

2026 (TTM)

-4,336.82%

0.00%

2022

-4,336.82%

0.00%

2021

-4,336.82%

1,356.53%

2020

-297.75%

-10.80%

2019

-333.80%

-57.10%

2018

-778.07%

418.13%

2017

-150.17%

-65.75%

2016

-438.41%

152.31%

2015

-173.76%

331.38%

2014

-40.28%

-90.98%

2013

-446.40%

-95.27%

2012

-9,447.17%

509.60%

2011

-1,549.72%

273.68%

2010

-414.72%

0.00%

2009

0.00%

2008

0.00%

2007

0.00%

2006

0.00%

2005

0.00%

2004

0.00%

2003

0.00%

2002

0.00%

-100.00%

2001

-1,046,045.90%

42.56%

2000

-733,774.14%

13,744.82%

1999

-5,299.99%

0.00%

Firma	Marża operacyjna	Różnica w marży operacyjnej	Kraj
Novo Nordisk A/S NVO.US	41.30%	-100.01%	DK
Vertex Pharmaceuticals Incorporated VRTX.US	35.45%	-100.01%	US
Regeneron Pharmaceuticals, Inc. REGN.US	24.95%	-100.01%	US
UCB SA UCB.BR	25.32%	-100.01%	BE
Argenx SE ARGX.US	25.64%	-100.01%	NL

Firma

Marża operacyjna

Różnica w marży operacyjnej

Kraj